The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders
Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoi...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universitat Pompeu Fabra |
| Repositorio: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/52218 |
| Acceso en línea: | http://hdl.handle.net/10230/52218 http://dx.doi.org/10.1111/bph.15656 |
| Access Level: | acceso abierto |
| Palabra clave: | Aminopeptidase N Dual enkephalinase inhibitor Neprilysin Opioid Opioid use disorders δ-opioid receptor μ-opioid receptor |
| id |
ES_fa48df03ddcbefc7278cddfebbebcd90 |
|---|---|
| oai_identifier_str |
oai:repositori.upf.edu:10230/52218 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disordersÁlvarez-Pérez, BeltránPoras, HervéMaldonado, Rafael, 1961-Aminopeptidase NDual enkephalinase inhibitorNeprilysinOpioidOpioid use disordersδ-opioid receptorμ-opioid receptorDespite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual enkephalinase inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins and increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggests that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the major limitations of exogenous opioids, representing a novel approach to overcome the problem of opioid use disorders.Wiley202220222023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/52218http://dx.doi.org/10.1111/bph.15656reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésBr J Pharmacol. 2023;180(7):879-93© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.http://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/522182026-06-12T07:21:37Z |
| dc.title.none.fl_str_mv |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| title |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| spellingShingle |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders Álvarez-Pérez, Beltrán Aminopeptidase N Dual enkephalinase inhibitor Neprilysin Opioid Opioid use disorders δ-opioid receptor μ-opioid receptor |
| title_short |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| title_full |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| title_fullStr |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| title_full_unstemmed |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| title_sort |
The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders |
| dc.creator.none.fl_str_mv |
Álvarez-Pérez, Beltrán Poras, Hervé Maldonado, Rafael, 1961- |
| author |
Álvarez-Pérez, Beltrán |
| author_facet |
Álvarez-Pérez, Beltrán Poras, Hervé Maldonado, Rafael, 1961- |
| author_role |
author |
| author2 |
Poras, Hervé Maldonado, Rafael, 1961- |
| author2_role |
author author |
| dc.subject.none.fl_str_mv |
Aminopeptidase N Dual enkephalinase inhibitor Neprilysin Opioid Opioid use disorders δ-opioid receptor μ-opioid receptor |
| topic |
Aminopeptidase N Dual enkephalinase inhibitor Neprilysin Opioid Opioid use disorders δ-opioid receptor μ-opioid receptor |
| description |
Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual enkephalinase inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins and increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggests that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the major limitations of exogenous opioids, representing a novel approach to overcome the problem of opioid use disorders. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2022 2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10230/52218 http://dx.doi.org/10.1111/bph.15656 |
| url |
http://hdl.handle.net/10230/52218 http://dx.doi.org/10.1111/bph.15656 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Br J Pharmacol. 2023;180(7):879-93 |
| dc.rights.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:Repositorio Digital de la UPF instname:Universitat Pompeu Fabra |
| instname_str |
Universitat Pompeu Fabra |
| reponame_str |
Repositorio Digital de la UPF |
| collection |
Repositorio Digital de la UPF |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869425170716819456 |
| score |
15,811543 |